Phaseline

Targets › SN38

SN38: drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 1; Oncology; next expected readout Dec 2026.

Open in Phaseline: the race on SN38, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Valent TechnologiesVAL-413 (Orotecan®)
Topoisomerase I inhibitor
SN38Phase 1Solid TumorsDec 2026

Conditions

Solid Tumors (1)

Modalities

small molecule (1)

Companies

Valent Technologies (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.